Fused compounds that inhibit vanilloid receptor subtype 1 (VR1) receptor
US8487116B2 · kind B2 · utility
5Cited by
17References
14Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Nov 9, 2011 |
| Grant date | Jul 16, 2013 |
| Priority date | — |
| Expiry date | Jan 16, 2032 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07D403/12
- WIPO fieldOrganic fine chemistry
- WIPO sectorChemistry
Abstract
The present invention discloses novel compounds of general formula (I)or a pharmaceutically acceptable salt or prodrug thereof (in which X1-X5, R5-R8b, Z1-Z2 and Ar1 are defined herein), a method for inhibiting the VR1 receptor in mammals using these compounds, a method for controlling pain in mammals, and pharmaceutical compositions including those compounds and a process for making those compounds.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.